The RSV vaccine is recommended and available for the following groups:

• Pregnant women from 28 weeks of pregnancy onward, to protect their babies for the first few months after birth.
• Adults aged 75 to 79, and those who turned 80 after September 1, 2024, as older adults are at higher risk of serious RSV complications.
• Adults aged 50 to 74 who have increased risk of severe RSV due to underlying health conditions like chronic heart or lung disease, weakened immune system, or living in nursing homes.
• In some regions, RSV vaccines are also available at pharmacies for eligible pregnant women and older adults.
• Infants born April 1, 2025, or later, up to 8 months old during RSV season, and some high-risk children under 2 years are eligible for RSV immunization or monoclonal antibody injections, depending on local programs.

This eligibility is based on the latest programs in countries like the UK, US, Canada, Australia, the Netherlands, and Ireland, reflecting current RSV vaccine public health guidance as of 2025.